BioCentury | Apr 30, 2009
Distillery Techniques

Technology: Drug platforms

...for tissue regeneration and repair. In hESCs, the mTOR inhibitor Rapamune rapamycin suppressed expression of cyclin G2...
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...cyclin G2 (CCNG2) In vitro studies and clinical specimen analysis suggest that expression of SHARP-1 and CCNG2...
...gene expression datasets from primary breast cancer patients, those with low expression of SHARP-1 and CCNG2...
...expression of the gene signature. Next steps include investigating the mechanisms by which SHARP-1 and CCNG2...
Items per page:
1 - 2 of 2